202 related articles for article (PubMed ID: 38592162)
1. The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis.
Iannone G; Pompili E; De Venuto C; Pratelli D; Tedesco G; Baldassarre M; Caraceni P; Zaccherini G
J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592162
[TBL] [Abstract][Full Text] [Related]
2. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.
Praktiknjo M; Abu-Omar J; Chang J; Thomas D; Jansen C; Kupczyk P; Schepis F; Garcia-Pagan JC; Merli M; Meyer C; Strassburg CP; Pieper CC; Trebicka J
JHEP Rep; 2021 Jun; 3(3):100264. PubMed ID: 34013182
[TBL] [Abstract][Full Text] [Related]
3. Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.
Garcia-Tsao G
Semin Intervent Radiol; 2005 Dec; 22(4):278-86. PubMed ID: 21326706
[TBL] [Abstract][Full Text] [Related]
4. Where does TIPS fit in the management of patients with cirrhosis?
García-Pagán JC; Saffo S; Mandorfer M; Garcia-Tsao G
JHEP Rep; 2020 Aug; 2(4):100122. PubMed ID: 32671331
[TBL] [Abstract][Full Text] [Related]
5. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
[TBL] [Abstract][Full Text] [Related]
6. Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.
Horhat A; Bureau C; Thabut D; Rudler M
United European Gastroenterol J; 2021 Mar; 9(2):203-208. PubMed ID: 32819214
[TBL] [Abstract][Full Text] [Related]
7. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.
Rajesh S; George T; Philips CA; Ahamed R; Kumbar S; Mohan N; Mohanan M; Augustine P
World J Gastroenterol; 2020 Oct; 26(37):5561-5596. PubMed ID: 33088154
[TBL] [Abstract][Full Text] [Related]
8. Cirrhosis and Portal Hypertension: How Do We Deal with Ascites and Its Consequences.
Tonon M; Piano S
Med Clin North Am; 2023 May; 107(3):505-516. PubMed ID: 37001950
[TBL] [Abstract][Full Text] [Related]
9. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.
Benmassaoud A; Freeman SC; Roccarina D; Plaz Torres MC; Sutton AJ; Cooper NJ; Iogna Prat L; Cowlin M; Milne EJ; Hawkins N; Davidson BR; Pavlov CS; Thorburn D; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD013123. PubMed ID: 31978257
[TBL] [Abstract][Full Text] [Related]
10. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
Tan HK; James PD; Sniderman KW; Wong F
J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
[TBL] [Abstract][Full Text] [Related]
12. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
Narahara Y; Kanazawa H; Fukuda T; Matsushita Y; Harimoto H; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Nakatsuka K; Sakamoto C
J Gastroenterol; 2011 Jan; 46(1):78-85. PubMed ID: 20632194
[TBL] [Abstract][Full Text] [Related]
13. Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis.
Zhu P; Dong S; Sun P; Belgaumkar AP; Sun Y; Cheng X; Zheng Q; Li T
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012358. PubMed ID: 37531575
[TBL] [Abstract][Full Text] [Related]
14. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
15. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.
Siramolpiwat S
World J Gastroenterol; 2014 Dec; 20(45):16996-7010. PubMed ID: 25493012
[TBL] [Abstract][Full Text] [Related]
16. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites.
Garcia-Tsao G
Nat Clin Pract Gastroenterol Hepatol; 2006 Jul; 3(7):380-9. PubMed ID: 16819501
[TBL] [Abstract][Full Text] [Related]
17. Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt.
Zhao D; Zhang G; Wang M; Zhang C; Li J
Clin Mol Hepatol; 2019 Jun; 25(2):210-217. PubMed ID: 30897897
[TBL] [Abstract][Full Text] [Related]
18. Innovative approaches to the management of ascites in cirrhosis.
Wong F
JHEP Rep; 2023 Jul; 5(7):100749. PubMed ID: 37250493
[TBL] [Abstract][Full Text] [Related]
19. The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions.
Deltenre P; Zanetto A; Saltini D; Moreno C; Schepis F
Hepatology; 2023 Feb; 77(2):640-658. PubMed ID: 35665949
[TBL] [Abstract][Full Text] [Related]
20. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
